22nd Century to Re-Launch and Expand VLN(R) Presence in South Korea
22nd Century to Re-Launch and Expand VLN(R) Presence in South Korea
Mocksville, North Carolina--(Newsfile Corp. - July 9, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, today announced a new agreement for full-scale commercial rollout of its VLN reduced nicotine content cigarettes in South Korea. The new agreement with 22nd Century's local partner, Nico-Tech Korea, Inc., follows an initial test launch conducted in 2022 that identified product updates needed to align with local South Korean cigarette characteristics and appeal to the specific preferences of adult smokers in Korea.
22nd Century Group, Inc. (納斯達克: XXII) 是一家專注於尼古丁危害減少和合約製造的菸草產品公司,總部位於北卡羅來納的莫克斯維爾,日前宣佈其 VLN 低尼古丁含量香菸正式進入韓國市場並全面推廣。這一新協議是22世紀與其當地合作伙伴 Nico-Tech Korea, Inc. 達成的,該公司在2022年進行了初步測試,以確定產品更新,以符合本地韓國香菸的特徵並迎合韓國成年吸菸者的特定喜好。
Said Larry Firestone, Chairman and CEO: "South Korea is a unique market characterized by high smoking rates and a corresponding high commitment from its government to reduce the harms of smoking. Based on the pilot launch in 2022, we made key product modifications to better align with specific characteristics of combusted cigarettes preferred by South Korea's adult smokers. We have made those changes and are now ready to fully enter the market with VLN export shipments to South Korea anticipated to begin later this year."
22nd Century Group, Inc. (納斯達克: XXII) 的董事長兼首席執行官 Larry Firestone 表示:"鑑於韓國市場的高吸菸率以及政府爲減少吸菸危害所做出的高度承諾,韓國市場是一個獨特的市場。基於2022年的試點發行,我們對燃燒香菸,特別是韓國成年吸菸者喜歡的特定產品特徵進行了關鍵的產品修改。我們已經進行了這些改變,並準備在今年晚些時候開始向韓國輸出 VLN 低尼古丁香菸產品。"
"This re-launch with our original partner, Nico-Tech, demonstrates their commitment to smoking harm reduction and making VLN products a key part of the South Korean market through the diverse array of local retail channels they serve. We are working with Nico-Tech to plan a full launch event for the Fall of 2024, including on-site support."
"通過與我們原來的合作伙伴 Nico-Tech 的這次再次合作,表明他們致力於減少吸菸危害,並將 VLN 產品作爲韓國市場通過他們服務的各種本地零售渠道的一個關鍵部分。我們正在與 Nico-Tech 合作規劃一個完整的推廣活動,包括現場支持。"
South Korea represents an estimated $1.6 billion1 tobacco market and was the first international market to commence sales of VLN reduced nicotine content cigarettes. While tobacco products use has declined since signing into law the 1995 National Health Promotion Act and subsequent government actions, the prevalence of smoking remains high in certain segments of the South Korean population.3 It is estimated that one in three adult men in South Korea2 are smokers, and an estimated 6% of adult women smoke.
韓國是一個估計有 16 億美元的菸草市場,並是第一個開始銷售 VLN 低尼古丁含量香菸的國際市場。儘管自簽署1995年國家健康促進法和後續政府行動以來,菸草製品使用率已經下降,但在韓國某些人群中吸菸的普及率仍然很高。據估計,韓國男性成年人中有三分之一爲吸菸者,女性成年人中約有 6% 吸菸。
Nico-Tech will be responsible for all local marketing activities to generate consumer demand and awareness in South Korea. The new agreement includes minimum order quantities to support the initial stocking and re-stocking needs of the planned South Korean distribution.
Nico-Tech 將負責所有本地營銷活動,在韓國產生消費者需求和意識。新協議包括最小訂單量,以支持計劃的韓國分銷的初次進貨和再進貨需求。
1
2
3
1
2
我們的董事會認爲,我們的薪酬政策和實踐是合理的,並適當地將我們的員工利益與股東的利益相一致。董事會認爲,對於我們的高管和其他員工的激勵性薪酬與收益掛鉤的事實鼓勵採取有利於公司短期和長期盈利的行動。此外,薪酬委員會審查有關我們的薪酬政策和實踐的變化,以確保此類政策和實踐不會鼓勵我們的高管和其他員工採取可能導致公司出現重大不利影響的行動。
About 22nd Century Group, Inc.
關於22世紀集團公司
22nd Century Group, Inc. (NASDAQ: XXII) is an agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA's Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. The Company is a subsequent participating manufacturer under the Master Settlement Agreement ("MSA") and vertically integrated for the production of its both own products and contract manufacturing operations ("CMO"), which consist primarily of branded filtered cigars and conventional cigarettes.
22nd Century Group, Inc. (納斯達克: XXII) 是一家農業生物技術公司,專注於菸草危害減少、低尼古丁菸草和通過植物科學改善健康和福祉。憑藉幾十項專利,使其能夠控制菸草植物中的尼古丁生物合成,公司已經開發出專有的低尼古丁含量(RNC)菸草植株和香菸,這成爲美國FDA全面計劃的關鍵,旨在解決吸菸導致的廣泛死亡和疾病問題。該公司於2021年12月獲得了唯一的FDA修改風險的菸草產品(MRTP)授權,可燃香菸。公司是《和解協議》的後續參與制造商,垂直整合,生產其自己的產品和合同製造操作(CMO),主要包括品牌過濾雪茄和傳統香菸。
Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.
Learn more about VLN at tryvln.com.
欲了解更多,請訪問 xxiicentury.com,在Twitter、領英和YouTube上了解我們公司的最新動態。
了解有關VLN的更多信息,請訪問 tryvln.com。
Cautionary Note Regarding Forward-Looking Statements
關於前瞻性聲明的謹慎說明
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-Looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-Looking statements include, but are not limited to, statements regarding (i) our strategic alternatives and cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 28, 2024 and Quarterly Report on Form 10-Q filed on May 15, 2024. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.
除歷史信息外,本新聞發佈中包含的所有聲明、期望和假設均爲前瞻性聲明,包括但不限於我們的全年業務展望。前瞻性聲明通常包含諸如“預測”、“相信”、“考慮”、“繼續”、“可能”、“估計”、“期望”、“探索”、“預見”、“目標”、“指引”、“打算”、“可能性”、“計劃”、“潛力”、“預測”、“初步”、“可能”的類似表述。前瞻性聲明包括但不限於以下方面的聲明:(i)我們的戰略替代方案和成本削減舉措,(ii)我們對監管和執法的期望,包括我們能否獲得新法規的豁免,(iii)我們的財務和業務表現,以及(iv)我們對公司業務中斷保險索賠的預期。實際結果可能存在明顯或隱含的前瞻性聲明。造成實際結果有所不同的重要因素載於公司2024年3月28日提交的《10-K年度報告》和2024年5月15日提交的《10-Q季度報告》中的“風險因素”中。本發佈提供的所有信息截至本文發佈之日,公司不承擔任何更新前瞻性聲明的義務,也沒有意圖更新,除非有法律要求。
Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
mkreps@xxiicentury.com
214-597-8200
投資者關係與媒體聯繫
Matt Kreps
投資者關係
22世紀集團
mkreps@xxiicentury.com
214-597-8200
譯文內容由第三人軟體翻譯。